Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Xiaohua Chen,Xiaohua Chen,Xiaohua Chen,Xiaohua Chen,Xiaohua Chen,Taotao Zhang,Taotao Zhang,Taotao Zhang,Taotao Zhang,Wei Su,Wei Su,Wei Su,Wei Su,Zhihui Dou,Zhihui Dou,Zhihui Dou,Zhihui Dou,Dapeng Zhao,Dapeng Zhao,Dapeng Zhao,Dapeng Zhao,Xiaodong Jin,Xiaodong Jin,Huiwen Lei,Huiwen Lei,Huiwen Lei,Huiwen Lei,Jing Wang,Xiaodong Xie,Bo Cheng,Qiang Li,Qiang Li,Qiang Li,Qiang Li,Qiang Li,Qiang Li,Hong Zhang,Hong Zhang,Hong Zhang,Hong Zhang,Hong Zhang,Cuixia Di,Cuixia Di,Cuixia Di,Cuixia Di,Cuixia Di,Cuixia Di
DOI: https://doi.org/10.1038/s41419-022-05408-1
2022-11-18
Abstract:TP53, a crucial tumor suppressor gene, is the most commonly mutated gene in human cancers. Aside from losing its tumor suppressor function, mutant p53 (mutp53) often acquires inherent, novel oncogenic functions, which is termed “gain-of-function”. Emerging evidence suggests that mutp53 is highly associated with advanced malignancies and poor prognosis, which makes it a target for development of novel cancer therapies. Herein, we provide a summary of our knowledge of the mutp53 types and mutp53 spectrum in cancers. The mechanisms of mutp53 accumulation and gain-of-function are also summarized. Furthermore, we discuss the gain-of-function of mutp53 in cancers: genetic instability, ferroptosis, microenvironment, and stemness. Importantly, the role of mutp53 in the clinic is also discussed, particularly with regard to chemotherapy and radiotherapy. Last, emphasis is given to emerging strategies on how to target mutp53 for tumor therapy. Thus, this review will contribute to better understanding of the significance of mutp53 as a target for therapeutic strategies.
cell biology